IN VITRO EFFECTS OF MEVASTATIN AND BIOLOGICAL PREPARATIONS UPON ACTIVATION OF EBV-SPECIFIC CD4+T LYMPHOCYTES FROM THE PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract. Present study concerned in vitro modifying effects of mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra upon antigen-induced activation of peripheral EBV-specific CD4+T-lymphocytes from the patients with rheumatoid arthritis (RA). When compared with healthy persons, the RA patients have...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
SPb RAACI
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/33b04b8675be44efab2fb398a6784976 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Abstract. Present study concerned in vitro modifying effects of mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra upon antigen-induced activation of peripheral EBV-specific CD4+T-lymphocytes from the patients with rheumatoid arthritis (RA). When compared with healthy persons, the RA patients have shown significantly decreased concentrations of antigen-activated EBV-specific CD4+T-cells. In healthy donors, mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra did not influence the CD4+, IFNγ+ cell concentrations. Neither there were any effects of the abovementioned drugs upon the numbers of EBV-specific CD4+T-cell subset among cultured mononuclear cells from RA patients. Thus, the cells from RA patients exhibit a decreased in vitro antigen-induced activation of EBV-specific CD4+T-cells, whereas statins and biological agents do not promote suppression of EBV-specific activation of CD4+T-cells. (Med. Immunol., 2011, vol. 13, n 2-3, pp 285-290) |
|---|